Related Experiment Video
Updated: Apr 14, 2026
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report
1Division of Pediatric Neurology, University of Iowa Children's Hospital, Iowa City, Iowa.
Background:
Malignant migrating partial seizures in infancy is a devastating pharmacoresistent epileptic encephalopathy of unknown etiology characterized by onset in the first 6 months of life, continuous migrating focal seizures with corresponding multifocal electroencephalographic discharges, developmental deterioration, and early mortality. Recent widespread interest in the nonpsychoactive component of the cannabis plant, cannabidiol, as a potential treatment for refractory devastating epilepsies has led to individual trials initiated by families or physicians in states that have legalized medical marijuana with anecdotal success.
Patient Description:
We describe a now 10-month-old boy with malignant migrating partial seizures in infancy who made developmental gains and demonstrated sustained seizure reduction with the addition of cannabidiol to his antiepileptic regimen.
Conclusion:
This report supports a role for cannabidiol in the treatment of malignant migrating partial seizures in infancy.
Insights
Cannabidiol (CBD) shows promise for treating malignant migrating partial seizures in infancy, a severe form of epilepsy. This study reports developmental gains and seizure reduction in an infant treated with CBD.
Area of Science:
- Pediatric Neurology
- Epilepsy Research
- Cannabinoid Therapeutics
Background:
- Malignant migrating partial seizures in infancy (MMPI) is a severe, drug-resistant epilepsy with unknown causes.
- MMPI presents in early infancy with continuous seizures, developmental decline, and high mortality.
- Cannabidiol (CBD), a non-psychoactive cannabis compound, is being explored for refractory epilepsies.
Observation:
- A 10-month-old infant diagnosed with MMPI was treated with cannabidiol.
- The infant received CBD as an add-on therapy to his existing antiepileptic drugs.
Findings:
- The infant demonstrated significant developmental progress.
- Sustained reduction in seizure frequency was observed after initiating CBD treatment.
Implications:
- This case suggests cannabidiol may be a viable treatment option for MMPI.
- Further research is warranted to explore CBD's efficacy and safety in treating this rare epilepsy syndrome.
More Related Videos
05:25Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
Published on: December 29, 2021
10:22Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
Published on: December 6, 2016
